| Market Capitalization (Millions $) |
786 |
| Shares
Outstanding (Millions) |
63 |
| Employees |
54 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-71 |
| Cash Flow (TTM) (Millions $) |
-7 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Design Therapeutics Inc is a biotechnology company that is focused on developing transformative treatments for serious degenerative conditions that are caused by RNA dysregulation. The company was founded in 2017 by two leading RNA-targeting scientists from Scripps Research, Matthew Disney, PhD, and Adrian Krainer, PhD, along with entrepreneur Jean-Pierre Sommadossi, PhD, who serves as the CEO.
Design Therapeutics is headquartered in San Diego, California and is primarily focused on developing small molecule drugs that specifically target RNA molecules that are malfunctioning in a variety of disease states. RNA is a critical component of gene expression and can play a causal role in many diseases, including neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as genetic disorders such as myotonic dystrophy.
The company has a proprietary platform technology called 'DTx RNA Targeting Platform' that enables precision medicine technologies for rigorous target identification and selection followed by the design precise small molecules as potential therapeutics. The platform encompasses in-depth genomics data, small molecule pharmacological properties, and proprietary algorithms for identifying potential RNA targets.
One of the lead programs for Design Therapeutics is in the development of DM1, a small molecule investigational therapy for myotonic dystrophy type 1 (DM1). DM1 is an inherited neuromuscular disorder that affects multiple organs and systems of the body, including the nervous system, heart, and muscle. There is currently no cure for DM1, only supportive therapies for the symptoms. Design Therapeutics is focused on developing a small molecule DM1 drug candidate that selectively inhibits the abnormal protein produced by DM1's genetic mutation.
Furthermore, Design Therapeutics has various collaborations with other biotech companies and institutions. In 2021, it announced a partnership with Regeneron to utilize its precision medicine platform towards discovering RNA-targeting therapeutics.
In summary, Design Therapeutics Inc is a biotechnology company that is focused on developing small molecule drugs that target RNA molecules that are implicated in degenerative diseases, with emphasis on neuromuscular disorders. With a proprietary platform technology and an experienced team, the company aims to bring transformative treatments to the clinic.
Company Address: 6005 Hidden Valley Road Zagreb 92011 City of Zagreb
Company Phone Number: 293-4900 Stock Exchange / Ticker: NASDAQ DSGN
|
1.64%